Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy

文献类型： 外文期刊

第一作者： Hu, Li

作者： Hu, Li;Cheng, Xingbo;Han, Zhibin;Yin, Yibo;Wang, Sida;Feng, Yumeng;Lin, Zhiguo;Binder, Zev;O'Rourke, Donald M.;Weng, Changjiang;Wu, Anhua

作者机构：

关键词： glioblastoma multiform; UBE2S; PTEN; pAkt; chemo-radiotherapy; prognosis

期刊名称：FRONTIERS IN ONCOLOGY （ 影响因子：6.244； 五年影响因子：6.264 ）

ISSN： 2234-943X

年卷期： 2021 年 11 卷

页码：

收录情况： SCI

摘要： Glioblastoma is the most common and lethal brain cancer globally. Clinically, this cancer has heterogenous molecular and clinical characteristics. Studies have shown that UBE2S is highly expressed in many cancers. But its expression profile in glioma, and the correlation with clinical outcomes is unknown. RNA sequencing data of glioma samples was downloaded from the Chinese Glioma Genome Atlas and The Cancer Genome Atlas. A total of 114 cases of glioma tissue samples (WHO grades II-IV) were used to conduct protein expression assays. The molecular and biological characteristics of UBE2S, and its prognostic value were analyzed. The results showed that high UBE2S expression was associated with a higher grade of glioma and PTEN mutations. In addition, UBE2S affected the degree of malignancy of glioma and the development of chemo-radiotherapy resistance. It was also found to be an independent predictor of worse survival of LGG patients. Furthermore, we identified five UBE2S ubiquitination sites and found that UBE2S was associated with Akt phosphorylation in malignant glioblastoma. The results also revealed that UBE2S expression was negatively correlated with 1p19q loss and IDH1 mutation; positively correlated with epidermal growth factor receptor amplification and PTEN mutation. This study demonstrates that UBE2S expression strongly correlates with glioma malignancy and resistance to chemo-radiotherapy. It is also a crucial biomarker of poor prognosis.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序